Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Exact Therapeutics AS's Enterprise Value is €5.77 Mil.
Exact Therapeutics AS's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-5.72 Mil. Therefore, Exact Therapeutics AS's EV-to-OCF for today is -1.01.
The historical rank and industry rank for Exact Therapeutics AS's EV-to-OCF or its related term are showing as below:
FRA:56F'
s EV-to-OCF Range Over the Past 10 Years
Min: -0.81 Med: 0 Max: -0.81
Current: -0.81
During the past 9 years, the highest EV-to-OCF of Exact Therapeutics AS was -0.81. The lowest was -0.81. And the median was .
FRA:56F's EV-to-OCF is ranked worse than 66.76% of 1408
companies
in the Biotechnology industry
Industry Median: -3.68
vs FRA:56F: -0.81
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Exact Therapeutics AS (FRA:56F) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Exact Therapeutics AS's PE Ratio (TTM) for today is calculated as:
Exact Therapeutics AS's share price for today is €0.032.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Exact Therapeutics AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.117.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Exact Therapeutics AS's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Exact Therapeutics AS EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Exact Therapeutics AS's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Exact Therapeutics AS's EV-to-OCF falls into.
Exact Therapeutics AS's current Enterprise Value is €5.77 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Exact Therapeutics AS's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-5.72 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exact Therapeutics AS (FRA:56F) has a EV-to-OCF of -1.01 as of Sep. 05, 2026. According to the industry distribution chart, Exact Therapeutics AS ranks #940 out of 1408 companies in the Biotechnology industry, placing it in the top 66.8%.
Is Exact Therapeutics AS's EV-to-OCF too high?
Exact Therapeutics AS's current EV-to-OCF is -1.01. Based on the distribution chart, Exact Therapeutics AS ranks #940 out of 1408 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Exact Therapeutics AS has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Exact Therapeutics AS's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Exact Therapeutics AS ranks #940 out of 1408 companies for EV-to-OCF. This places Exact Therapeutics AS in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Exact Therapeutics AS's current EV-to-OCF is -1.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exact Therapeutics AS stock overvalued right now?
Exact Therapeutics AS (FRA:56F) has a current EV-to-OCF of -1.01. The current EV-to-OCF is -1.01. Exact Therapeutics AS's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Exact Therapeutics AS (FRA:56F), the current EV-to-OCF is -1.01 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Exact Therapeutics AS is a clinical-stage biotechnology company focused on developing Acoustic Cluster Therapy (ACT), a non-invasive ultrasound-mediated technology for targeted enhancement of therapeutic agents. Its ACT platform (PS101) is being evaluated mainly in oncology, including pancreatic cancer and liver metastases, with additional applications in immuno-oncology, gene therapy, and central nervous system disorders.
22GF Score
Get the complete analysis for FRA:56F
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:56F has been successfully added to your 
